Acute and Long-term Impact of Cancer Treatment on Head and Neck Cancer Patients: FIT4TREATMENT (F4T)
31. juli 2021 oppdatert av: Associacao de Investigacao de Cuidados de Suporte em Oncologia
Acute and Long-term Impact of Cancer Treatment on Quality-of-life, Physical and Cognitive Function of Head and Neck Cancer Patients
Head and Neck Squamous Cell Carcinoma (HNSCC) is the 6th most common cancer.
Most cases are diagnosed in locally advanced stages, with treatment involving multimodal approach with combinations of radiotherapy, surgery and chemotherapy.
The aggressive nature of HNSCCs and treatment modalities are associated with important acute and late toxicities that often promote temporary or definitive treatment interruption and may compromised the capability to tolerate subsequent treatments.
Thus, the aim of this study is to analyze the acute and long-term impact of cancer treatment on quality of life, physical and cognitive function of HNSCC patients diagnosed with a locally advanced disease.
Studieoversikt
Status
Avsluttet
Forhold
Detaljert beskrivelse
Potential cases will be identified at the multidisciplinary head and neck group meeting.
If the case meets eligibility an informed consent will be presented to the patient.
Interested participants will be scheduled for baseline assessment before the beginning of treatment (M0).
At the end of CRT patients will be submitted to a second assessment (M1).
Follow-up assessments will occur 16th to 18th weeks after the treatment is completed (M2).
Patients proposed to surgery or induction chemotherapy will also be submitted to an additional assessment before the beginning of CRT (Mc / Mic).
Studietype
Observasjonsmessig
Registrering (Faktiske)
21
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Vila Nova De Gaia, Portugal
- Centro Hospitalar Vila Nova de Gaia / Espinho
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
N/A
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
Eligible patients had to have more than 18 years, diagnosed with stage III to IVB HNSCC and proposed for primary treatment with curative intent - surgery or induction chemotherapy before chemoradiotherapy (CRT) or CRT alone.
Exclusion criteria was: 1) synchronous tumors or other comorbidities with associated uncontrolled symptoms; 2) inability to provide informed consent; 3) expected inability to fulfil the propose schedule and follow-up.
Beskrivelse
Inclusion Criteria:
- Patients older than 18 years.
- Diagnosis of locally advanced head and neck cancer (oral cavity, oropharynx, hypopharynx, larynx), stage III-IVB.
- Proposed for primary treatment with curative intent - surgery or induction chemotherapy before chemoradiotherapy (CRT) or CRT alone.
Exclusion Criteria:
- Synchronous tumors or other comorbidities with associated uncontrolled symptoms.
- Inability to provide informed consent.
- Expected inability to fulfil the propose schedule and follow-up.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Quality of life (acute)
Tidsramme: Change of global quality of life score from baseline to the end of treatment
|
Global quality of life score evaluated by EORTC QLQ-C30 questionnaire (range in score from 0 to 100, high score represents a high level of functioning)
|
Change of global quality of life score from baseline to the end of treatment
|
|
Quality of life (long-term)
Tidsramme: Change of global quality of life score from baseline to 4 months after the treatment is completed
|
Global quality of life score evaluated by EORTC QLQ-C30 questionnaire (range in score from 0 to 100, high score represents a high level of functioning)
|
Change of global quality of life score from baseline to 4 months after the treatment is completed
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Fatigue (acute)
Tidsramme: Change of fatigue score from baseline to the end of treatment
|
Fatigue score evaluated by EORTC QLQ-C30 questionnaire (range in score from 0 to 100, high score represents high level of symptomatology / problems)
|
Change of fatigue score from baseline to the end of treatment
|
|
Fatigue (long-term)
Tidsramme: Change of fatigue score from baseline to 4 months after the treatment is completed
|
Fatigue score evaluated by EORTC QLQ-C30 questionnaire (range in score from 0 to 100, high score represents high level of symptomatology / problems)
|
Change of fatigue score from baseline to 4 months after the treatment is completed
|
|
Social functioning (acute)
Tidsramme: Change of body mass index from baseline to the end of treatment
|
Social functioning score evaluated by EORTC QLQ-C30 questionnaire (range in score from 0 to 100, high score represents a high level of functioning)
|
Change of body mass index from baseline to the end of treatment
|
|
Social functioning (long-term)
Tidsramme: Change of body mass index from baseline to 4 months after the treatment is completed
|
Social functioning score evaluated by EORTC QLQ-C30 questionnaire (range in score from 0 to 100, high score represents a high level of functioning)
|
Change of body mass index from baseline to 4 months after the treatment is completed
|
|
Body composition (acute)
Tidsramme: Change of body mass index from baseline to the end of treatment
|
Body mass index, evaluated by bioelectrical impedance (BMI kg/m^2).
|
Change of body mass index from baseline to the end of treatment
|
|
Body composition (long-term)
Tidsramme: Change of body mass index from baseline to 4 months after the treatment is completed
|
Body mass index, evaluated by bioelectrical impedance (BMI kg/m^2).
|
Change of body mass index from baseline to 4 months after the treatment is completed
|
|
Cognitive function (acute)
Tidsramme: Change of MoCA score from baseline to the end of treatment
|
Evaluated by the Montreal Cognitive Assessment and the Functional Assessment of Cancer Therapy-Cognitive (MoCA score range between 0 and 30, a score of 26 or over is considered to be normal).
|
Change of MoCA score from baseline to the end of treatment
|
|
Cognitive function (long-term)
Tidsramme: Change of MoCA score from baseline to 4 months after the treatment is completed
|
Evaluated by the Montreal Cognitive Assessment and the Functional Assessment of Cancer Therapy-Cognitive (MoCA score range between 0 and 30, a score of 26 or over is considered to be normal).
|
Change of MoCA score from baseline to 4 months after the treatment is completed
|
|
Dysphagia (acute)
Tidsramme: Change of EAT-10 score from baseline to the end of treatment
|
Severity of dysphagia assessed by Eating Assessment Tool (EAT-10 total score ranges from 0 to 40, with a score ≥ 3 indicative of dysphagia)
|
Change of EAT-10 score from baseline to the end of treatment
|
|
Dysphagia (long-term)
Tidsramme: Change of EAT-10 score from baseline to 4 months after the treatment is completed
|
Severity of dysphagia assessed by Eating Assessment Tool (EAT-10 total score ranges from 0 to 40, with a score ≥ 3 indicative of dysphagia)
|
Change of EAT-10 score from baseline to 4 months after the treatment is completed
|
|
Dysphagia (acute)
Tidsramme: Change of FOIS score from baseline to the end of treatment
|
Severity of dysphagia assessed by Functional Oral Intake Scale (FOIS ranges from 1 to 7)
|
Change of FOIS score from baseline to the end of treatment
|
|
Dysphagia (long-term)
Tidsramme: Change of FOIS score from baseline to 4 months after the treatment is completed
|
Severity of dysphagia assessed by Functional Oral Intake Scale (FOIS ranges from 1 to 7)
|
Change of FOIS score from baseline to 4 months after the treatment is completed
|
|
Nutritional status (acute)
Tidsramme: Change of PG-SGA total score from baseline to the end of treatment
|
Evaluated by the Patient-Generated Subjective Global Assessment (PG-SGA range from 0-35 with a higher score reflecting a greater risk of malnutrition).
|
Change of PG-SGA total score from baseline to the end of treatment
|
|
Nutritional status (long-term)
Tidsramme: Change of PG-SGA total score from baseline to 4 months after the treatment is completed
|
Evaluated by the Patient-Generated Subjective Global Assessment (PG-SGA range from 0-35 with a higher score reflecting a greater risk of malnutrition).
|
Change of PG-SGA total score from baseline to 4 months after the treatment is completed
|
|
Handgrip maximal isometric muscle strength (acute)
Tidsramme: Change of muscle strength from baseline to the end of treatment
|
Measured with manual dynamometers (Kgf).
|
Change of muscle strength from baseline to the end of treatment
|
|
Handgrip maximal isometric muscle strength (long-term)
Tidsramme: Change of muscle strength from baseline to 4 months after the treatment is completed
|
Measured with manual dynamometers (Kgf).
|
Change of muscle strength from baseline to 4 months after the treatment is completed
|
|
Quadriceps maximal isometric muscle strength (acute)
Tidsramme: Change of muscle strength from baseline to the end of treatment
|
Measured with manual dynamometers (Kgf).
|
Change of muscle strength from baseline to the end of treatment
|
|
Quadriceps maximal isometric muscle strength (long-term)
Tidsramme: Change of muscle strength score from baseline to 4 months after the treatment is completed
|
Measured with manual dynamometers (Kgf).
|
Change of muscle strength score from baseline to 4 months after the treatment is completed
|
|
Sit-to-stand test (acute)
Tidsramme: Change of repetitions from baseline to the end of treatment
|
Sit-to-stand test during 30 seconds
|
Change of repetitions from baseline to the end of treatment
|
|
Sit-to-stand test (long-term)
Tidsramme: Change of repetitions from baseline to 4 months after the treatment is completed
|
Sit-to-stand test during 30 seconds
|
Change of repetitions from baseline to 4 months after the treatment is completed
|
|
Physical function (acute)
Tidsramme: Change of distance from baseline to the end of treatment
|
6 minutes walking test (meters).
|
Change of distance from baseline to the end of treatment
|
|
Physical function (long-term)
Tidsramme: Change of distance from baseline to 4 months after the treatment is completed
|
6 minutes walking test (meters)
|
Change of distance from baseline to 4 months after the treatment is completed
|
|
Progression free survival
Tidsramme: 2 years follow-up
|
Defined as the time from the beginning of treatment to the date of first progression or death (whichever occurs first) and will be censored at last follow-up date if the patient does not have the event.
A progression (local, regional or distant) will be assumed accordingly to the imaging evaluation and/or histopathologic confirmation.
|
2 years follow-up
|
|
Overall survival
Tidsramme: 2 years follow-up
|
Defined as the time from the beginning of treatment to the date of death from any cause, for patients who do not die, it will be censored at their last follow-up date.
|
2 years follow-up
|
|
Capability of tolerating subsequent treatments
Tidsramme: 2 years follow-up
|
Defined as the proportion of patients that complete the first cycle of the first line palliative chemotherapy after a documented progression (considering all patients with a formal indication).
|
2 years follow-up
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Inês Leão, MD, Centro Hospitalar Vila Nova de Gaia / Espinho
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. juni 2019
Primær fullføring (Faktiske)
3. mars 2020
Studiet fullført (Faktiske)
3. mars 2020
Datoer for studieregistrering
Først innsendt
25. april 2021
Først innsendt som oppfylte QC-kriteriene
31. juli 2021
Først lagt ut (Faktiske)
9. august 2021
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
9. august 2021
Siste oppdatering sendt inn som oppfylte QC-kriteriene
31. juli 2021
Sist bekreftet
1. juli 2021
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 102/2019
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .